GeneDx Holdings Corp. shares fell over 49% after the company reported weaker-than-expected Q1 results and lowered its 2026 revenue guidance from $540-555 million to $475-490 million. The company also revealed a $31.3 million goodwill impairment related to its recent acquisition of Fabric Genomics. Following these disclosures, a class action lawsuit was filed alleging that GeneDx misled investors about the importance of Fabric Genomics, reimbursement rates, and profit margins. Investors have 60 days to join the lawsuit or seek lead plaintiff status.
GeneDx Holdings Corp. faces a class action lawsuit alleging it misled investors about the viability of Fabric Genomics, a company it acquired. The lawsuit claims GeneDx and executives made false statements and failed to disclose problems that hurt bu...
GeneDx Holdings Corp. shares dropped 49% on May 5, 2025, after the company reported a massive tenfold increase in net loss for Q1 2026 and cut its full-year 2026 revenue guidance by 12%. The company’s average reimbursement rate fell short due to a sh...
A class action lawsuit has been filed against GeneDx Holdings Corp. and some of its officers for allegedly misleading investors between April 16, 2025, and May 4, 2026. The complaint claims the company made false statements and failed to disclose key...
